Dipti Patel-Donnelly

Assistant Professor

19992019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2019

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Awan, F. T., Thirman, M. J., Patel-Donnelly, D., Assouline, S., Rao, A. V., Ye, W., Hill, B. & Sharman, J. P., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

2018

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

Burke, J. M., Shustov, A., Essell, J., Patel-Donnelly, D., Yang, J., Chen, R., Ye, W., Shi, W., Assouline, S. & Sharman, J., Jan 1 2018, (Accepted/In press) In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma

Andorsky, D. J., Kolibaba, K. S., Assouline, S., Forero-Torres, A., Jones, V., Klein, L. M., Patel-Donnelly, D., Smith, M., Ye, W., Shi, W., Yasenchak, C. A. & Sharman, J. P., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

2017

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Friedberg, J. W., Forero-Torres, A., Bordoni, R. E., Cline, V. J. M., Patel-Donnelly, D., Flynn, P. J., Olsen, G., Chen, R., Fong, A., Wang, Y. & Yasenchak, C. A., Dec 28 2017, In : Blood. 130, 26, p. 2829-2837 9 p.

Research output: Contribution to journalArticle

WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY

Kim, J. S., Jaworski, L., Patel-Donnelly, D., Nussenblatt, R. B. & Nida Sen, H., Jan 1 2017, In : Retinal Cases and Brief Reports. 11, 2, p. 152-155 4 p.

Research output: Contribution to journalArticle

2014

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Berenson, J. R., Hilger, J. D., Yellin, O., Dichmann, R., Patel-Donnelly, D., Boccia, R. V., Bessudo, A., Stampleman, L., Gravenor, D., Eshaghian, S., Nassir, Y., Swift, R. A. & Vescio, R. A., Jan 1 2014, In : Leukemia. 28, 7, p. 1529-1536 8 p.

Research output: Contribution to journalArticle

2013

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

Berenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel-Donnelly, D., Siegel, R. S., Kewalramani, T., Gorak, E. J., Nassir, Y., Swift, R. A. & Mayo, D., Feb 1 2013, In : British Journal of Haematology. 160, 3, p. 321-330 10 p.

Research output: Contribution to journalArticle

2009

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

De Vos, S., Goy, A., Dakhil, S. R., Saleh, M. N., McLaughlin, P., Belt, R., Flowers, C. R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S. A., Holladay, C., Zhang, T. & Boral, A. L., Oct 20 2009, In : Journal of Clinical Oncology. 27, 30, p. 5023-5030 8 p.

Research output: Contribution to journalArticle

2003

Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy

Patel-Donnelly, D., Väänänen, H., Jiroušková, M., Hoffmann, T., Bodian, C. & Coller, B. S., Feb 1 2003, In : Blood. 101, 3, p. 929-936 8 p.

Research output: Contribution to journalArticle

1999

Protein 4.1R-deficient mice are viable but have erythroid membrane skeleton abnormalities

Shi, Z. T., Afzal, V., Coller, B., Patel-Donnelly, D., Chasis, J. A., Parra, M., Lee, G., Paszty, C., Stevens, M., Walensky, L., Peters, L. L., Mohandas, N., Rubin, E. & Conboy, J. G., Feb 1 1999, In : Journal of Clinical Investigation. 103, 3, p. 331-340 10 p.

Research output: Contribution to journalArticle